[Evaluation of Drug Cost-Saving Effects of Drug Vial Optimization Using an Anticancer Drug Compounding Robot: A Single-center Study].

This study aimed to evaluate the drug cost-saving effects of drug vial optimization (DVO) using an anticancer drug compounding robot in a single institution. Robotic preparations, drug costs, and wastage were evaluated from April to July 2022. Cost-saving simulations were conducted assuming same-day or 7-day DVO. From September to December 2022, DVO was performed for paclitaxel, carboplatin, and etoposide, and actual cost savings were evaluated. During the initial period, 2613 doses (42.0%) were prepared by the robot, with a wastage rate of 2.7%. The simulated cost savings were approximately ¥2.8 million (same-day) and ¥7.49 million (7-days). After the introduction of DVO, 291 vials were saved, equivalent to ¥790000. In conclusion, DVO using an anticancer drug compounding robot can reduce anticancer drug wastage and may contribute to drug cost savings in clinical practice.